DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $52,138,959 | -76.4% | 210,153 | -77.2% | 0.05% | -76.1% |
Q2 2023 | $221,177,760 | +34.7% | 921,574 | +41.5% | 0.23% | +28.4% |
Q1 2023 | $164,172,807 | +46.9% | 651,376 | +54.7% | 0.18% | +41.9% |
Q4 2022 | $111,741,820 | +132.3% | 421,000 | +126.1% | 0.12% | +117.5% |
Q3 2022 | $48,094,000 | -25.2% | 186,201 | -26.5% | 0.06% | -25.0% |
Q2 2022 | $64,264,000 | +76.6% | 253,490 | +104.3% | 0.08% | +123.5% |
Q1 2022 | $36,399,000 | -29.5% | 124,089 | -21.0% | 0.03% | -19.0% |
Q4 2021 | $51,647,000 | -40.3% | 156,977 | -44.7% | 0.04% | -46.2% |
Q3 2021 | $86,478,000 | +1182.1% | 284,057 | +1030.2% | 0.08% | +1200.0% |
Q2 2021 | $6,745,000 | -76.4% | 25,134 | -80.2% | 0.01% | -78.6% |
Q1 2021 | $28,585,000 | -36.1% | 126,997 | -36.9% | 0.03% | -30.0% |
Q4 2020 | $44,732,000 | +109.7% | 201,370 | +103.2% | 0.04% | +81.8% |
Q3 2020 | $21,334,000 | +34.0% | 99,078 | +10.1% | 0.02% | +15.8% |
Q2 2020 | $15,916,000 | -63.9% | 90,009 | -71.8% | 0.02% | -72.1% |
Q1 2020 | $44,127,000 | +136.6% | 318,813 | +162.4% | 0.07% | +223.8% |
Q4 2019 | $18,647,000 | -59.4% | 121,493 | -61.8% | 0.02% | -63.2% |
Q3 2019 | $45,882,000 | +10.7% | 317,676 | +9.6% | 0.06% | +11.8% |
Q2 2019 | $41,430,000 | +707.3% | 289,880 | +645.7% | 0.05% | +628.6% |
Q1 2019 | $5,132,000 | -88.1% | 38,875 | -90.7% | 0.01% | -88.1% |
Q4 2018 | $43,108,000 | -82.1% | 418,031 | -81.1% | 0.06% | -79.6% |
Q3 2018 | $240,562,000 | +15.3% | 2,213,901 | +4.7% | 0.29% | +6.2% |
Q2 2018 | $208,607,000 | +70.1% | 2,113,976 | +68.8% | 0.27% | +62.9% |
Q1 2018 | $122,615,000 | -21.1% | 1,252,325 | -25.2% | 0.17% | -22.0% |
Q4 2017 | $155,480,000 | +14.1% | 1,675,067 | +5.5% | 0.21% | +2.4% |
Q3 2017 | $136,231,000 | +86.6% | 1,588,141 | +83.5% | 0.21% | +72.7% |
Q2 2017 | $73,025,000 | +326.1% | 865,329 | +331.9% | 0.12% | +303.3% |
Q1 2017 | $17,138,000 | +554.4% | 200,373 | +495.7% | 0.03% | +500.0% |
Q4 2016 | $2,619,000 | -51.5% | 33,638 | -51.2% | 0.01% | -50.0% |
Q3 2016 | $5,401,000 | +1022.9% | 68,896 | +1346.8% | 0.01% | +900.0% |
Q2 2016 | $481,000 | -99.2% | 4,762 | -99.3% | 0.00% | -98.9% |
Q4 2015 | $63,627,000 | +131.3% | 685,051 | +112.2% | 0.10% | +131.7% |
Q3 2015 | $27,506,000 | -68.1% | 322,800 | -67.9% | 0.04% | -68.0% |
Q2 2015 | $86,110,000 | -55.3% | 1,006,073 | -55.7% | 0.13% | -56.6% |
Q1 2015 | $192,607,000 | +97.3% | 2,268,631 | +99.1% | 0.30% | +134.1% |
Q4 2014 | $97,643,000 | +119.9% | 1,139,231 | +95.0% | 0.13% | +117.2% |
Q3 2014 | $44,397,000 | -52.4% | 584,328 | -50.7% | 0.06% | -54.0% |
Q2 2014 | $93,225,000 | -54.9% | 1,184,105 | -57.0% | 0.13% | -57.3% |
Q1 2014 | $206,662,000 | +45.3% | 2,755,480 | +49.6% | 0.30% | +52.1% |
Q4 2013 | $142,190,000 | +103.8% | 1,841,833 | +83.0% | 0.19% | +74.8% |
Q3 2013 | $69,774,000 | -15.1% | 1,006,541 | -22.4% | 0.11% | -27.9% |
Q2 2013 | $82,140,000 | – | 1,297,619 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |